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Abstract
Purpose: This study aims to investigate the role of
diffusion-weighted imaging (DWI) and T2-weighted
imaging (T2WI) in combination for the detection of
prostate cancer, specifically assessing the role of high b-
values (> 1000 s/mm2), with a systematic review and
meta-analysis of the existing published data.
Methods: The electronic databases MEDLINE, EM-
BASE, and OpenSIGLE were searched between inception
and September 1, 2017. Eligible studies were those that
reported the sensitivity and specificity of DWI and T2WI
for the diagnosis of prostate cancer by visual assessment
using a histopathologic reference standard. The QUA-
DAS-2 critical appraisal tool was used to assess the quality
of included studies. A meta-analysis with pooling of
sensitivity, specificity, likelihood, and diagnostic odds
ratios was undertaken, and a summary receiver-operating
characteristics (sROC) curve was constructed. Predeter-
mined subgroup analysis was also performed.
Results: Thirty-three studies were included in the final
analysis, evaluating 2949 patients. The pooled sensitivity
and specificitywere 0.69 (95%CI 0.68–0.69) and 0.84 (95%
CI 0.83–0.85), respectively, and the sROC AUC was 0.84
(95% CI 0.81–0.87). Subgroup analysis showed signifi-
cantly better sensitivity with high b-values (> 1000 s/
mm2). There was high statistical heterogeneity between
studies.
Conclusion: The diagnostic accuracy of combined DWI
and T2WI is good with high b-values (> 1000 s/mm
2)
seeming to improve overall sensitivity while maintaining
specificity. However, further large-scale studies specifi-
cally looking at b-value choice are required before a
categorical recommendation can be made.
Key words: Prostate cancer—Diffusion-weighted
imaging—T2-weighted imaging—b-value—Meta-
analysis
With a crude incidence of 134.3 per 100,000, prostate
cancer is the most common cancer in men, and the sec-
ond-biggest cause of cancer mortality [1, 2]. The quoted
incidence has increased in recent years; however, this
may be due to the use of prostate-specific antigen (PSA)
blood testing. The majority of suspected cases with either
a high PSA, abnormal digital rectal examination (DRE),
or suggestive symptoms, will undergo a transrectal
ultrasound guided biopsy (TRUS) to confirm and grade
a histopathologic diagnosis [3]. If this is positive and the
patient is a candidate for radical treatment, they will
receive multiparametric magnetic resonance imaging
(mpMRI) to assess the extent of cancer growth. How-
ever, there are now a substantial number of centers
choosing pre-biopsy mpMRI followed by a more-tar-
geted biopsy.
Multiparametric MRI is a well-established imaging
modality for assessing prostate cancer, predominately to
exclude extra-glandular spread and to judge how much
of the prostate is involved. It consists of multiple se-
quences, including T1- and T2-weighted imaging (T2WI),
diffusion-weighted imaging (DWI) and, in some in-
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stances, Dynamic contrast-enhanced (DCE) imaging.
Multiple meta-analyses have proven DWI to have good
diagnostic accuracy [4–6]; its contrast is governed by
numerous technical parameters, one of the most impor-
tant of these is the diffusion-weighting factor, or ‘b-va-
lue’. The b-value reflects the strength and timings of
magnetic field gradients applied to the patient, and
acquisition of multiple b-values permits calculation of an
apparent diffusion coefficient (ADC) map, which gives a
quantitative measure of tissue diffusion that has been
shown to have an inverse correlation with tumor Gleason
score [7]. Currently the recommendation is to use at least
two b-values, one of 50–100 s/mm2, 800–1000 s/mm2 and
if possible 1400–2000 s/mm2 [8, 9]. Theoretically,
increasing the maximum b-value results in a better con-
trast-to-noise ratio (CNR) because there is greater sup-
pression of normal prostate tissue signal, so resulting
tumors are more apparent. However, the tradeoff is a
reduced signal-to-noise ratio (SNR). Even though b-
values > 1400 is recommended, there is little evidence
supporting this and there is no widely accepted optimal
‘‘high b-value.’’ In a previous meta-analysis, Wu et al.
showed no benefit from increasing b-value but only one
paper in the analysis used b-values of over 1000 [4]. A
multitude of recent studies have shown high sensitivity
and specificity with higher b-values using both visual and
ADC value assessments [10–12]. For clinical relevance,
we hope to investigate the diagnostic accuracy achievable
by visual assessment of DWI in combination with T2WI
at high b-values > 1000 s/mm2.
Materials and methods
This review was registered with the PROSPERO Inter-
national prospective register of systematic reviews (ref-
erence number: 42016036196) prior to commencement
[13]. The review was carried out in accordance with the
preferred reporting items for systematic reviews and
meta-analysis (PRISMA) guidance [14].
A systematic review of the literature was indepen-
dently undertaken by two reviewers, who identiﬁed
studies that investigated the diagnostic accuracy of DWI
and T2WI MRI in the detection of prostate cancer.
Searches were performed using MEDLINE and EM-
BASE electronic databases, as well as OpenSIGLE to
explore sources of unpublished gray literature. The Sci-
ence Citation Index was used to identify articles which
cite those identified with the original search terms. Once
eligible studies were found, their reference lists were
manually searched for further potential papers. The
search strategy for MEDLINE, including Boolean
operators and MeSH terms, is presented in Table 1; the
same search strategy was used for each database with
alterations to suit. All studies were included up to the
date of the search: 1st of September 2017.
Eligibility
The eligibility criteria for the studies included within the
systematic review were that they used both DWI and
T2WI MRI in combination for the assessment of prostate
cancer; they were applied for the assessment of the pre-
treatment patient population with a histopathologic
reference standard, be that biopsy or radical prostatec-
tomy; they reported sufficient information to produce a
2 9 2 table (true positives, false positives, false negatives,
and true negatives) for calculation of sensitivity and
specificity; they were published in English; and they as-
sessed more than ten individual patients. To be included,
both T2WI and DWI sequences needed to be assessed
visually, with both sequences used to assess for tumor
presence rather than just for localization. The choice of
scoring system, such as Likert or PI-RADS, and whether
a sector-based or whole gland assessment was conducted
did not affect eligibility. Articles were excluded if they
did not satisfy the inclusion criteria above, or if they used
a combination of imaging sequences other than DWI and
T2WI so that individual data for the desired combination
could not be extracted. They were also excluded if an
ADC cutoff value was used to discriminate malignant
from benign tissue as opposed to visual assessment by
certified radiologists. Studies were not excluded by
country of origin, age of patients or study design.
Study identiﬁcation
Initially papers were reviewed by relevancy of title and
then abstract. Residual articles had their full text re-
viewed against the inclusion and exclusion criteria. This
was also done independently by the same two reviewers.
Any disagreement was solved by consensus or a third
expert reviewer if necessary.
Data extraction
The following data were extracted from each eligible
study: year of publication, country of origin, patient
group, number of patients, average age, and PSA, study
design (retrospective or prospective) and the
Table 1. MEDLINE search terms and strategy
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histopathologic reference standard used. Further infor-
mation on the imaging speciﬁcations was also gathered:
ﬁeld strength, coil used, ﬁeld-of-view, b-value set, and
whether they visually assessed DWI source images, ADC
maps, or both, for each patient. True positives, false
positives, false negatives, and true negatives were also
extracted for pooling results. In the case of multireader
studies, the most experienced was chosen for data
extraction. When insufficient data were available,
reviewers manually calculated them from other reported
statistics, when possible. All data extraction was inde-
pendently verified by two reviewers.
Quality assessment
The quality of the individual included paper’s method-
ology was assessed with the Quality Assessment of
Diagnostic Accuracy Studies (QUADAS-2) tool, a vali-
dated tool speciﬁcally designed to critically appraise
diagnostic accuracy studies [15]. This was also under-
taken independently by two reviewers and disagreement
resolved with consensual discussion consulting a third
expert reviewer if a consensus could not be met.
Statistical analysis
The sensitivity and speciﬁcity with 95% conﬁdence
intervals (CIs) were calculated for each included study
using the extracted details of the 2 9 2 tables, and forest
plots produced.
Initially, heterogeneity of studies was examined
visually using the data extraction tables. Then, statistical
analysis was performed using the inconsistency value (I2)
and Q statistics of the Chi squared value, for which an I2
value > 50% or p value < 0.10, respectively, represents
significant statistical heterogeneity. In these cases, a
random-effects model was applied to data pooling.
Pooled results for sensitivity, specificity, and diagnostic
odds ratio (DOR) with 95% CIs, and a summary re-
ceiver-operating characteristic (sROC) curve were also
presented.
To explore predictable sources of heterogeneity be-
tween the included studies, sensitivity and 1-speciﬁcity
were plotted on an ROC plane to visually assess the
presence or absence of a ‘shoulder arm’ shape, which
indicates a threshold effect. This was also tested statis-
tically with the Spearman correlation coefﬁcient of the
logit of sensitivity and logit of (1-speciﬁcity), with a p-
value < 0.05 suggesting a threshold effect. Subgroup
analysis was performed for; b-values (< 1000, 1000
and > 1000 s/mm2), field strength (1.5T and 3T), coil
type (endorectal and body), method of assessment (DWI
source images, ADC or both), reference standard (biopsy
and radical prostatectomy), tumor zone (peripheral or
transitional zone) and study design (retrospective and
prospective). If possible raw data was separated from
individual papers for each subgroup. Pooled sensitivities,
specificities, positive and negative likelihood ratios, and
meta-regression of diagnostic odds ratios were per-
formed for these subgroups with a p-value < 0.05
deemed as statistically significant.
Publication bias was not assessed as there is currently
no recognized or appropriate method that does so with
sufﬁcient power for diagnostic accuracy studies, and the
impact of publication bias is presently unknown for
studies of this type [16].
All statistical analysis was performed using Meta-
DiSc (version 1.4, Javier Zamora).
Results
Search results
With the above-presented search strategy, 2825 citations
were discovered, and after duplicates were removed,
there were left 1880 unique articles. A total of 33 studies
were included in the ﬁnal analysis after reviewing against
the eligibility criteria. The PRISMA ﬂowchart of the
search results is presented in Fig. 1.
Quality assessment
The full results of the QUADAS-2 appraisal are pre-
sented in Table 2. The strengths across the included
studies were that the vast majority used consecutive pa-
tient selection with appropriate inclusion and exclusion
Fig. 1. PRISMA flow diagram. ADC, apparent diffusion
coefficient; DWI, diffusion-weighted imaging; T2WI, T2-
weighted imaging.
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criteria. However, two studies [17, 18] limited their
investigation to transitional zone tumors and another
[19] to patients with ‘low risk’ cancer. Therefore a sub-
group analysis was deemed particularly important to
assess the differences between peripheral and transitional
zone tumors. Another strength was that all index tests
used were applicable to clinical practice, without any
nonstandard imaging methods. All but one study imaged
patients after a positive biopsy, while patients studied by
Tanimoto et al. had a pre-biopsy MRI [20]. A number of
studies did not state the timings between biopsy and
MRI [21–24], which could have implications if the timing
was too long causing a disparity between the images and
histopathology correlation or too short resulting in an
increased incidence of post-biopsy hemorrhage which
might limit accuracy. Kitajima et al. [25] and Morgan
et al. [26] reported delays between biopsy and imaging
much less than the recommended six weeks [27]. The
predominant weakness of included studies was applica-
bility of the patient groups, as studies were often limited
to patients who underwent radical prostatectomy. These
patients tend to be younger, with a narrower range of
tumor staging. However, this is acceptable to obtain a
reference test with low bias.
Study characteristics
The data extracted for study characteristics are described
in Tables 3, 4, and 5. There were 2949 patients across the
33 studies. The mean age (range) was 65.1 (41–86) years,
and PSA was 9 (0.4–130) ng/mL, respectively. The
majority of studies (n = 20) used a retrospective study
design as opposed to prospective (n = 13). Most of the
studies (n = 19) used 3T field strength, thirteen studies
used 1.5 T, and one study used both. Maximum b-values
across the studies ranged from 600 to 2000 with the
majority using 1000. Nine studies used an endorectal
coil. Nine studies used DWI source images for diagnosis,
while seven used ADC maps and seventeen used both.
Most studies (n = 20) used radical prostatectomy as the
reference standard while seven used TRUS biopsy, two
MRI guided biopsy, one transperineal biopsy and an-
other used a mixture of TRUS biopsy and radical
prostatectomies.
Meta-analysis
Visual assessment of the data extraction tables indicated
they were homogeneous enough to undertake a meta-
Table 2. QUADAS-2 quality assessment of included studies
Study Risk of bias Applicability
Patient selection Index test Reference test Flow and timing Patient selection Index test Reference test
Agha [43] 4 4 7 4 ? 4 4
Bains [44] 4 4 4 4 7 4 7
Baur [45] 4 4 7 ? 4 4 4
Brendle [46] 4 4 4 7 7 4 4
Costa [47] 4 7 7 ? 7 4 7
Doo [48] 4 4 4 4 7 4 4
Haider [49] 4 4 4 4 7 4 4
Hoeks [17] 7 4 4 4 7 4 4
Isabaert [21] 4 4 4 ? 7 4 4
Iwazawa [50] 4 4 7 4 4 4 4
Jung [18] 4 7 4 4 7 4 4
Katahira [51] 4 4 4 4 7 4 4
Kim [19] 7 4 4 4 7 4 4
Kitajima [25] 4 4 4 7 ? 4 4
Kuhl [33] 4 4 7 ? 4 4 4
Lim [52] 4 4 4 4 7 4 4
Loggitsi [53] 4 4 4 4 7 4 4
Morgan [26] 4 4 7 7 4 4 4
Ohgiya [54] 4 4 7 4 4 4 4
Petrillo [22] 4 4 7 ? 4 4 4
Rosenkrantz [55] 4 4 4 4 7 4 4
Rosenkrantz [56] 4 4 4 4 7 4 4
Shimofusa [57] 4 4 4 7 7 4 4
Shinmoto [58] 4 4 4 ? 7 4 4
Stanzione [59] ? ? 7 4 7 4 4
Tanimoto [60] 4 ? 7 4 4 4 4
Thestrup [61] 4 4 7 4 4 4 4
Ueno 2013 [12] 4 4 4 4 7 4 4
Ueno 2013 [23] 4 4 4 ? 7 4 4
Ueno 2015 [62] 4 4 4 ? 7 4 4
Vargas [63] 4 4 4 4 7 4 4
Yoshimitsu [64] 4 4 4 4 7 4 4
Yoshizako [65] 4 4 4 4 7 4 4
4 Low risk; 7 high risk; ? unclear risk
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analysis with pooling. The pooled sensitivity (Fig. 2) and
specificity (Fig. 3) of all included studies were 0.69 (95%
CI 0.68–0.69) and 0.84 (95% CI 0.83–0.85), respectively.
The pooled DOR was 12.27 (95% CI 9.60–15.68). The
sROC (Fig. 4) gave an AUC of 0.839, indicating good
diagnostic accuracy.
The I2 value and Chi-square Q were 94.6% and 882.53
(p < 0.001), respectively, for sensitivity and 96.7% and
1446.59 (p < 0.001) for specificity, indicating significant
statistical heterogeneity. The ROC plane (Supplementary
Fig. 1) did not show a ‘shoulder-arm’ shape; however,
the Spearman rank coefficient of the logit of sensitivity
against logit of (1-specificity) was 0.335 (p = 0.018),
indicating there could be heterogeneity due to a thresh-
old effect.
Sub-group analysis
The highest DORs were obtained when using ADC maps
with or without DWI for tumors assessment and for b-
values > 1000 s/mm2. Significantly higher sensitivity
was achieved using b-values > 1000 s/mm2, 3T field
strength, assessing PZ tumors, studies with a retrospec-
tive design and those using biopsy as a reference stan-
dard. Specificity improved significantly with a 1.5T field
strength, assessing TZ tumors, using ADC maps with or
without DWI and those studies using radical prostatec-
tomy as the reference standard. The complete subgroup
analysis is shown in Table 6.
Discussion
The ﬁndings from this study show the diagnostic accu-
racy of DWI and T2WI of prostate cancer is good when
using visual assessment. The greatest diagnostic accuracy
is achieved with b-values > 1000 s/mm2, and when
assessing lesions with both DWI source images and ADC
maps, although the interplay between sensitivity and
specificity can be significantly altered by the choice of
field strength and by whether tumors originate from the
peripheral or transitional zone. The overall strength of
the evidence on which this analysis was based was graded
as good by the QUADAS-2 critical appraisal tool [15].
However, there was a high degree of unknown statistical
heterogeneity, so care should be taken when interpreting
these results, and even though this review cannot specify
an optimal imaging protocol, it does highlight the likely
important factors to be considered.
Table 3. Principle characteristics of included studies
Study Year Country No. of patients Age (range) PSA (range) Design
Agha [43] 2015 Egypt 20 n/a n/a Pro
Bains [44] 2014 Switzerland 111 64a (43–82) n/a (0.7–112.2) Pro
Baur [45] 2016 Germany 44 66 (46–81) 12.3 (5.2–70) Pro
Brendle [46] 2016 Germany 15 66 (52–76) 11.8 (3.3–65.4) Pro
Costa [47] 2016 USA 49 63 (49–79) 11.2 (2.5–48.5) Pro
Doo [48] 2012 South Korea 51 63a (50–72) 11.5 (4.2–43.8) Retro
Haider [49] 2007 Canada 49 61a (46–75) 5.4a (0.9–26) Pro
Hoeks [17] 2013 Netherlands 28 n/a (45–73) n/a (1.9–44) Retro
Isabaert [21] 2013 Belgium 75 66a (49–64) 10.4 (1.5–70.9) Pro
Iwazawa [50] 2011 Japan 178 69 (41–86) n/a Retro
Jung [18] 2013 South Korea 156 59a (42–75) 4.9 (0.4–93.7) Retro
Katahira [51] 2011 Japan 201 69 (43–80) 13.2 (2.6–114) Retro
Kim [19] 2014 South Korea 100 63a (51–76) 6.5a (2.2–9.5) Retro
Kitajima [25] 2010 Japan 53 69a (56–84) 11.1a (4.2–112.1) Retro
Kuhl [33] 2017 Germany 542 64.8 (42–80) 8.5 (3.2–67.5) Pro
Lim [52] 2009 South Korea 52 65 (48–76) 10.5 (1.2–79.6) Retro
Loggitsi [53] 2017 Greece 26 63.7 (48–73) 8.1 (2–21.9) Pro
Morgan [26] 2007 UK 54 68 (52–80) 10 (n/a) Pro
Ohgiya [54] 2012 Japan 73 70 (n/a) 11.7a (n/a) Retro
Petrillo [22] 2014 Italy 136 66 (n/a) 6.8 (n/a) Pro
Rosenkrantz [55] 2011 USA 42 62 (47–76) 6.2 (1.3–32.5) Retro
Rosenkrantz [56] 2015 USA 106 62 (56–81) 6.9 (n/a) Retro
Shimofusa [57] 2005 Japan 37 71 (54–82) 21.8 (4.5–130) Retro
Shinmoto [58] 2015 Japan 87 n/a (51–75) n/a (2.8–35.2) Retro
Stanzione [59] 2016 Italy 82 65 (n/a) 8.8 (n/a) Pro
Tanimoto [60] 2007 Japan 83 67 (53–87) 19.4 (n/a) Pro
Thestrup [61] 2016 Denmark 204 64.1 (45–75) 14 (2.2–120) Retro
Ueno [12] 2013 Japan 73 67 (50–77) 9.51 (2.9–49) Retro
Ueno [23] 2013 Japan 80 67 (50–77) 9.51 (2.9–49) Retro
Ueno [62] 2015 Japan 31 65 (51–81) 8.6 (4.7–16.5) Retro
Vargas [63] 2011 USA 51 56a (46–74) 5.3 (0.4–62.2) Retro
Yoshimitsu [64] 2008 Japan 37 66 (56–75) 11.9 (0.7–54.8) Retro
Yoshizako [65] 2008 Japan 23 65a (52–76) n/a Retro
aMedian; N/A, not available; Pro, prospective; PSA, prostate-specific antigen (ng/mL); Retro, retrospective)
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Our pooled results match those of meta-analyses
investigating T2WI and DWI by Wu et al. and Tan et al.;
this is likely due to the large overlap of included studies
[28, 29]. Compared with Godley et al. and Jie et al. who
analyzed the use of DWI alone, we observed a higher
sensitivity but lower specificity [5, 30]. However, when
we compare the results for just peripheral zone tumors,
our pooled results are similar. This would suggest that
the addition of T2WI improves the sensitivity for diag-
nosing transitional zone tumors; however, neither God-
ley nor Jie et al. presented a subgroup for TZ tumors or
comparison [10]. This finding supports the present con-
sensus that T2WI with DWI should be the predominant
imaging protocol for diagnosing TZ tumors [9].
We observed a signiﬁcant increase in sensitivity using
a maximum b-value > 1000 s/mm2, and improved
specificity with a maximum b-value of ‡ 1000 s/mm2.
The improved contrast-to-noise ratio at higher b-values,
resulting from the relative suppression of normal pros-
tate tissue, would explain the increase in sensitivity by
making tumors more visually apparent. Two of the
studies [23, 24] also used computed high b-values. These
synthetic data extrapolated from low b-value datasets
showed relatively decreased sensitivity and increased
specificity compared to the equivalent acquired b-values.
There has been limited research comparing the diagnos-
tic accuracy of computed DWI to standard DWI, but the
method shows promise with reduced distortion and
ghosting and improved tumor conspicuity [31, 32].
We also note that all studies using b-values > 1000 s/
mm2 were limited to a maximum b-value of 2000 s/mm2,
except the study by Kuhlet al [33]. Wang et al. and
Metens et al. found b-values of 1500 s/mm2 gave a better
tumor contrast and image quality than b-values of 1,000
or 2000 s/mm2and Kuhl et al. using a b-value of 1400 s/
mm2, produced some of the highest sensitivities and
specificities [33–35]. However, more data on the diag-
nostic accuracy of b  1,500 DWI are required. Fur-
thermore, the maximum b-value, the minimum b-value,
and the number of b-values have all been shown to have
a strong influence on the calculated ADC values [36].
However, there is little evidence about their impact on
diagnostic accuracy with visual assessment [10, 36].
All but two of the included studies in this analysis
used b = 0 s/mm2 as the minimum b-value, but the
number of b-values ranged from two to seven. Tho¨rmer
et al. found that using just two b-values and a minimum
b-value of 50 s/mm2 gave an improved qualitative image
Table 4. Imaging and methodological characteristics of included studies
Study Field strength Endorectal coil FOV (cm) b-value Reference AS Method
Agha [43] 3T N 30 9 30 0, 1000 Bx U Both
Bains [44] 3T N n/a 0, 500, 1000 RP Y Both
Baur [45] 3T Both 20 9 20 0, 100, 500, 1000 MR N Both
Brendle [46] 3T N 27.6 9 28 50, 800 RP U Both
Costa [47] 3T Both 16 9 16 0–2000 Mix U Both
Doo [48] 3T N 28 9 28 0, 1000 RP U ADC
Haider [49] 1.5T Y 14 9 14 0, 600 RP U ADC
Hoeks [17] 3T Y 20.4 9 20.4 0, 50, 500, 800 RP U Both
Isabaert [21] 1.5T N 30.9 9 38 0, 50, 100, 500, 1000 RP U DWI
Iwazawa [50] 1.5T N 30 9 30 0, 1000 Bx U DWI
Jung [18] 1.5T/3T Y 12 9 12/14 9 14 0, 1000 RP U ADC
Katahira [51] 1.5T N 35 9 35 0, 1000, 2000 RP U DWI
Kim [19] 3T N 34 9 16.8 0, 100, 1000 RP Y Both
Kitajima [25] 3T N 35 9 25 0, 1000 Bxa N Both
Kuhl [33] 3T N 21 9 21 0, 800, 1000, 1400 MR U Both
Lim [52] 1.5T Y 22 9 22 0, 1000 RP Y ADC
Loggitsi [53] 1.5T N 10 9 10 0, 250, 500, 750, 1000 RP U Both
Morgan [26] 1.5T Y 20 9 20 0, 300, 500, 800 Bxa Y ADC
Ohgiya [54] 3T N 35 9 35 0, 500, 1000, 2000 Bx U DWI
Petrillo [22] 1.5T Y 13.6 9 16 0, 50, 100, 150, 300, 600, 800 Bx N Both
Rosenkrantz [55] 1.5T N 30 9 24.4 0, 500, 1000 RP U DWI
Rosenkrantz [56] 3T N 20 9 20/28 9 21.8 50, 1000, 2000 RP U Both
Shimofusa [57] 1.5T N 20 9 20 0, 1000 Mix U DWI
Shinmoto [58] 3T N 24 9 24 0, 1000 RP Y ADC
Stanzione [59] 3T N 20 9 20 0, 400, 2000 Bx U Both
Tanimoto [60] 1.5T N 36 9 36 0, 1000 Bx U Both
Thestrup [61] 3T U 19 9 19 0, 100, 800, 2000 Mix Y Both
Ueno [12] 3T N 45 9 45 0, 1000, 2000 RP Y DWI
Ueno [23] 3T N n/a 0, 1000, 2000 RP Y DWI
Ueno [62] 3T N 45 9 36 0, 2000 RP Y DWI
Vargas [63] 3T Y 14 9 14 0, 700/0, 1000 RP U ADC
Yoshimitsu [64] 1.5T N 24 9 24 0, 500, 1000 RP U Both
Yoshizako (65) 1.5T N 42 9 21 0, 1000 RP Y Both
aTransperineal biopsy; AS, antispasmodic; Bx, biopsy; FOV, field-of-view; Mix, mixture of Bx and RP; MR, Magnetic resonance imaging guided
biopsy; N, no; RP, radical prostatectomy; T, tesla; U, unclear; Y, yes
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score versus data with a minimum b-value of 0 s/mm2
[37]. However, they tested only a limited number of
combinations, and used a maximum b-value of just
800 s/mm2. The significant heterogeneity of b-value
choice in the included studies makes it extremely difficult
to provide a conclusion that high b-values are indeed
superior for diagnostic accuracy. The individual studies
that tested multiple b-value sets on the same cohort do,
however, show improved diagnostic accuracy using
b = 2,000 as opposed to 1000 or lower. Further studies
directly comparing b-value sets of different maximum,
minimum, and a number of intermediary b-values would
be required to make a stronger recommendation of b-
value choice.
DOR was not signiﬁcantly different between 1.5T and
3T studies (p = 0.418), but 3T studies showed a signifi-
cantly higher sensitivity and significantly lower speci-
ficity than those performed at 1.5T. Higher field
strengths have the advantage of increased SNR, which
can be traded for better spatial and temporal resolutions;
they also lead to increased susceptibility artifact and
signal heterogeneity, and there is conflicting evidence
with respect to the categorical advantage of 3T over 1.5 T
[38]. There is a trend toward better diagnostic accuracy
with 3T in our study, although this may be because these
systems allow the use of higher b-values, which improve
diagnostic accuracy. This result reflects the recommen-
dations of PIRADS v2 that 1.5T and 3T are both ade-
quate, but 3T is regarded optimal if available [9].
For a few of the studies, it was possible to separate
the results for PZ and TZ, and we found signiﬁcantly
higher sensitivity for the PZ, but higher speciﬁcity for
Table 5. Diagnostic performance of included studies
Study TP FP FN TN Sens Spec Notes
Agha [43] 10 1 5 4 0.67 0.80
Bains [44] 73 7 7 24 0.91 0.77
Baur [45] 14 11 0 18 0.97 0.62 Body coil
10 7 1 21 0.91 0.75 Endorectal coil
Brendle [46] 17 2 12 149 0.59 0.99
Costa [47] 20 19 06 73 0.44 0.79 Body coil
76 51 22 145 0.78 0.74 Endorectal coil
Doo [48] 113 21 58 216 0.66 0.91
Haider [49] 120 39 29 204 0.81 0.84
Hoeks [17] 65 39 47 101 0.58 0.72 TZ
Isabaert [21] 444 79 546 731 0.45 0.90
Iwazawa [50] 238 223 80 883 0.75 0.80
Jung [18] 91 62 84 699 0.52 0.92 TZ
Katahira [51] 971 559 616 2669 0.61 0.83 bmax = 1000
1162 332 425 2896 0.73 0.90 bmax = 2000
Kim [19] 17 7 22 72 0.44 0.91
Kitajima [25] 75 19 24 306 0.76 0.94
Kuhl [33] 138 49 9 346 0.94 0.88
Lim [52] 199 49 28 348 0.88 0.88
Loggitsi [53] 43 33 62 330 0.41 0.91
Morgan [26] 64 56 78 126 0.45 0.69
Ohgiya [54] 25 5 30 13 0.45 0.72 bmax = 500
43 4 12 14 0.78 0.78 bmax = 1000
42 2 13 16 0.76 0.89 bmax = 2000
Petrillo [22] 18 48 7 63 0.72 0.57
Rosenkrantz 2011 [55] 61 29 59 103 0.51 0.78
Rosenkrantz 2015 [56] 34 13 28 561 0.55 0.98 bmax = 1000
46 10 16 564 0.74 0.98 bmax = 2000
Shimofusa [57] 96 11 15 56 0.86 0.84
Shinmoto [58] 93 12 58 185 0.62 0.94
Stanzione [59] 29 1 5 52 0.85 0.98
Tanimoto [60] 37 6 7 33 0.84 0.85
Thestrup [61] 65 116 3 20 0.96 0.15
Ueno 2013 [12] 258 87 83 156 0.76 0.64 bmax = 1000
276 79 65 164 0.81 0.68 bmax = 2000
Ueno 2013 [23] 270 119 57 194 0.83 0.62 bmax = 1000
275 105 52 208 0.84 0.66 bmax = 2000
272 95 55 218 0.83 0.70 bmax = c2000
Ueno 2015 [62] 101 63 20 64 0.83 0.50 bmax = 2000
86 51 35 76 0.71 0.60 bmax = c2000
Vargas [63] 65 10 42 157 0.61 0.94
Yoshimitsu [64] 105 29 42 46 0.71 0.61
Yoshizako (65) 21 2 5 14 0.81 0.88 TZ
b, b-value; c, computed; FN, false negative; FP, false positive; PZ, peripheral zone; sens, sensitivity; spec, specificity; TN, true negative; TP, true
positive; TZ, transitional zone
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TZ. Often TZ tumors are of a lower grade than those
found in the PZ, so they may be less apparent on imaging
[39, 40]. There is also difficulty in differentiating malig-
nancy from benign nodules common in the TZ, which are
often heterogeneous and can demonstrate restricted dif-
fusion. Along with the relative rarity of TZ tumors this
may explain the drop in sensitivity but the overall DOR
was not significantly different. It may be that different
imaging parameters are needed for optimal diagnosis of
peripheral or transitional zone disease.
Our results showed a signiﬁcant increase in both
sensitivity and speciﬁcity when using ADC maps with or
without DWI source images for diagnostic assessment, as
opposed to using DWI source images alone. There are
many advantages to using ADC maps which might ex-
plain this change. Firstly, ADC maps give a quantitative
measure of tissue diffusion, and are particularly useful in
differentiating areas which have high signal on DWI
images due to T2 shine-through, such as post-biopsy
hemorrhage; this leads to reduced false positives and
improved specificity versus weighted images. The ADC
value can also be used to help confirm malignant lesions,
which have low ADCs due to restricted diffusion, and
this would explain the higher sensitivity seen.
Retrospective studies investigated men with previ-
ously conﬁrmed prostate cancer, and therefore the
readers knew there was cancer present in each prostate
examined. This may cause the readers to be more liberal
with diagnosing suspicious lesions in borderline cases
where there were no other lesions in the gland, explaining
the signiﬁcantly higher sensitivity.
Using radical prostatectomy as the reference standard
allows the assessment of individual tumors within the
gland and is a more accurate method of deﬁning tumor.
TRUS biopsy is ‘blind’ and only samples a small area of
the prostate, with a 20–30% false negative rate. This
would lead to increased false positives on imaging,
decreasing the speciﬁcity as we observe in the subgroup
analysis.
This systematic review has a few limitations. Our
search was, ﬁrst, limited by a ﬁnite number of databases
although those chosen contain the majority of the rele-
Fig. 2. Forest plot of sensitivity for detecting prostate cancer
including 95% CI, I2 value, and Q statistic. CI, confidence
interval; I2, inconsistency value.
Fig. 3. Forest plot of specificity for detecting prostate cancer
including 95% CI, I2 value, and Q statistic. CI, confidence
interval, I2, inconsistency value.
T. J. Syer et al.: The diagnostic accuracy of high b-value diffusion- and T2-weighted imaging
vant journals, and by exploring the gray literature and
hand-searching references, we believe the search strategy
was of sufﬁcient sensitivity. Speciﬁc databases for the
research question were sought, but none existed. Second,
the search was limited to the English language. The
majority of articles are published in English, but there
may be data in other languages that we did not include in
this meta-analysis. We did not assess for publication bias
for reasons stated in the statistical analysis section. The
degree to which publication bias impacts diagnostic tests
is unknown [16]. We did not review the exact T2WI
parameters for the included studies, which could explain
some of the heterogeneity seen. Reader experience is
another factor which we did not assess as it was often
poorly reported and in different formats such as years
practicing, years reporting prostate mpMRI, or number
of prostate mpMRIs. It is recognized that reader expe-
rience is important in interpreting mpMRI and should be
Fig. 4. Summary receiver-
operating characteristic
(SROC) curve for the
detection of prostate cancer.
AUC, area under the curve.
Table 6. Subgroup analysis and meta-regression
Group (number of studies) Sensitivity Specificity DOR I2 (%) P-value
Total 0.69 (0.68–0.69) 0.84 (0.83–0.85) 12.268 (9.60–15.68) 90.7
b-value 0.068
< 1000 (n = 7) 0.60 (0.56–0.64) 0.80 (0.78–0.83) 8.02 (3.18–20.26) 91.4
1000 (n = 23) 0.64 (0.62–0.65) 0.85 (0.84–0.85) 12.56 (9.56–16.50) 86.0
> 1000 (n = 13) 0.78(0.76–0.79) 0.83 (0.82–0.84) 14.32 (9.06–22.65) 92.0
Field strength 0.418
1.5 T (n = 14) 0.64 (0.63–0.65) 0.85 (0.84–0.86) 10.68 (7.34–15.55) 94.0
3 T (n = 28) 0.76 (0.75–0.78) 0.81 (0.79–0.82) 13.77 (9.54–19.88) 87.6
Coil 0.597
Body (n = 33) 0.68 (0.67–0.69) 0.85 (0.84–0.85) 13.06 (10.05–16.97) 90.4
Endorectal (n = 9) 0.68 (0.65–0.71) 0.84 (0.84–0.85) 10.40 (4.87–22.24) 93.1
Tumor zone 0.239
PZ (n = 6) 0.71 (0.70–0.73) 0.84 (0.82–0.85) 12.64 (7.13–22.41) 94.4
TZ (n = 11) 0.66 (0.64–0.68) 0.88 (0.87–0.88) 13.46 (8.08–22.44) 92.6
Assessment method 0.070
DWI (n = 12) 0.68 (0.67–0.69) 0.82 (0.81–0.83) 8.91 (6.8–11.68) 90.2
ADC map (n = 7) 0.66 (0.64–0.69) 0.89 (0.87–0.90) 15.44 (6.8–35.05) 93.8
Both (n = 20) 0.72 (0.70–0.75) 0.86 (0.85–0.87) 18.58 (9.77–35.30) 90.0
Design 0.918
Prospective (n = 15) 0.59 (0.56–0.61) 0.81 (0.80–0.83) 11.93 (6.61–21.54) 89.2
Retrospective (n = 28) 0.71 (0.70–0.72) 0.84 (0.84–0.85) 12.56 (9.57–16.49) 91.3
Reference standard 0.420
RP (n = 26) 0.67 (0.66–0.68) 0.85 (0.85–0.86) 12.09 (9.24–15.81) 91.4
Biopsy (n = 13) 0.73 (0.70–0.76) 0.81 (0.80–0.83) 15.83 (7.27–34.44) 91.3
CI, confidence interval; DOR, diagnostic odds ratio; I2, inconsistency value; T, tesla; PZ peripheral zone; TZ transitional zone; DWI diffusion-
weighted imaging; ADC, apparent diffusion coefficient; RP, radical prostatectomy
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considered when implementing prostate imaging [41, 42].
Although diagnostic accuracy is very important for pros-
tate cancer assessment, there are other aims of mpMRI
which have not been assessed in this meta-analysis: for
example, assessment of extracapsular extension, seminal
vesicle or lymph node involvement, and the ability of
mpMRI to quantify tumor size and volume. These find-
ings are all used in staging of disease and are relevant to
decisions about optimal imaging sequences.
In conclusion, the diagnostic accuracy of combined
diffusion- and T2-weighted magnetic resonance imaging
for prostate cancer detection is good, and our results
support the PI-RADS v2 guidelines [9]. The use of b-
values > 1000 s/mm2 seem to improve the sensitivity
while maintaining specificity. However, due to large
amounts of heterogeneity, we cannot categorically rec-
ommend using maximum b-values up to 2000 s/mm2 for
all DWI protocols for prostate cancer assessment. Fur-
ther large-scale study investigating optimal b-value
maximum, minimum, and number of b-values for the
visual assessment of prostate cancer is required.
Compliance with ethical standards
Funding This research did not receive any specific grant from any
funding agencies in the public, commercial, or not-for-profit sectors.
Conflict of interest Author Tom Syer declares he has no conflict of
interest. Author Keith Godley declares he has no conflict of interest.
Author Donnie Cameron declares he has no conflict of interest. Author
Paul Malcolm declares he has no conflict of interest.
Open Access This article is distributed under the terms of the Creative
Commons Attribution 4.0 International License (
http://creativecommons.org/licenses/by/4.0/), which permits unre-
stricted use, distribution, and reproduction in any medium, provided
you give appropriate credit to the original author(s) and the source,
provide a link to the Creative Commons license, and indicate if changes
were made.
References
1. Office for National Statistics. Cancer Statistics: Registrations Series
MB1. 2014
2. Cancer Research UK. Cancer Statistics April 2014
3. National Institute for Health and Clinical Excellence—Prostate
cancer: diagnosis and management. 2014 Contract No.: CG175
4. Wu LM, Xu JR, Ye YQ, Lu Q, Hu JN (2012) The clinical value of
diffusion-weighted imaging in combination with T2-weighted
imaging in diagnosing prostate carcinoma: a systematic review and
meta-analysis. Am J Roentgenol 199(1):103–110
5. Jie C, Rongbo L, Ping T (2014) The value of diffusion-weighted
imaging in the detection of prostate cancer: a meta-analysis. Eur
Radiol 24(8):1929–1941
6. Jin G, Su DK, Luo NB, et al. (2013) Meta-analysis of diffusion-
weighted magnetic resonance imaging in detecting prostate cancer.
J Comput Assist Tomogr 37(2):195–202
7. Tamada T, Sone T, Jo Y, et al. (2008) Apparent diffusion coeffi-
cient values in peripheral and transition zones of the prostate:
comparison between normal and malignant prostatic tissues and
correlation with histologic grade. J Magn Reson Imaging
28(3):720–726
8. Barentsz JO, Richenberg J, Clements R, et al. (2012) ESUR pros-
tate MR guidelines 2012. Eur Radiol 22(4):746–757
9. Radiology ACo. Prostate Imaging—Reporting and Data System
version 2. 2015.
10. Wang X, Qian Y, Liu B, et al. (2014) High-b-value diffusion-
weighted MRI for the detection of prostate cancer at 3 T. Clin
Radiol 69(11):1165–1170
11. Rosenkrantz AB, Hindman N, Lim RP, et al. (2013) Diffusion-
weighted imaging of the prostate: comparison of b1000 and b2000
image sets for index lesion detection. J Magn Reson Imaging
38(3):694–700
12. Ueno Y, Kitajima K, Sugimura K, et al. (2013) Ultra-high b-value
diffusion-weighted MRI for the detection of prostate cancer with
3-T MRI. J Magn Reson Imaging 38(1):154–160
13. National Institute for Health Reserach. PROSPERO, International
prospective register of systematic reviews. http://www.crd.
york.ac.uk/PROSPERO/.
14. Moher D, Liberati A, Tetzlaff J, Altman DG, The PG (2009)
Preferred reporting items for systematic reviews and meta-analyses:
the PRISMA statement. PLoS Med 6(7):e1000097
15. Whiting PF, Rutjes AWS, Westwood ME, et al. (2011) QUADAS-
2: a revised tool for the quality assessment of diagnostic accuracy
studies. Ann Intern Med 155(8):529–536
16. Deeks JJ, Macaskill P, Irwig L (2005) The performance of tests of
publication bias and other sample size effects in systematic reviews
of diagnostic test accuracy was assessed. J Clin Epidemiol
58(9):882–893
17. Hoeks CMA, Hambrock T, Yakar D, et al. (2013) Transition zone
prostate cancer: detection and localization with 3-T multipara-
metric MR imaging. Radiology 266(1):207–217
18. Jung IS, Donati OF, Vargas HA, et al. (2013) Transition zone
prostate cancer: incremental value of diffusion-weighted endorectal
MR imaging in tumor detection and assessment of aggressiveness.
Radiology 269(2):493–503
19. Kim JY, Kim SH, Kim YH, et al. (2014) Low-risk prostate cancer:
the accuracy of multiparametric MR imaging for detection. Radi-
ology 271(2):435–444
20. Tanimoto A, Nakashima J, Kohno H, Shinmoto H, Kurib-
ayashi S (2007) Prostate cancer screening: the clinical value of
diffusion-weighted imaging and dynamic MR imaging in com-
bination with T2-weighted imaging. J Magn Reson Imaging
25(1):146–152
21. Isebaert S, Van Den Bergh L, Haustermans K, et al. (2013) Mul-
tiparametric MRI for prostate cancer localization in correlation to
whole-mount histopathology. J Magn Reson Imaging 37(6):
1392–1401
22. Petrillo A, Fusco R, Setola SV, et al. (2014) Multiparametric MRI
for prostate cancer detection: performance in patients with pros-
tate-specific antigen values between 2.5 and 10 ng/mL. J Magn
Reson Imaging 39(5):1206–1212
23. Ueno Y, Takahashi S, Kitajima K, et al. (2013) Computed diffu-
sion-weighted imaging using 3-T magnetic resonance imaging for
prostate cancer diagnosis. Eur Radiol 23(12):3509–3516
24. Ueno Y, Takahashi S, Ohno Y, et al. (1048) Computed diffusion-
weighted MRI for prostate cancer detection: The influence of the
combinations of b-values. Br J Radiol 2015(88):20140738
25. Kitajima K, Kaji Y, Fukabori Y, et al. (2010) Prostate cancer
detection with 3 T MRI: comparison of diffusion-weighted imaging
and dynamic contrast-enhanced MRI in combination with T2-
weighted imaging. J Magn Reson Imaging 31(3):625–631
26. Morgan VA, Kyriazi S, Ashley SE, DeSouza NM (2007) Evalua-
tion of the potential of diffusion-weighted imaging in prostate
cancer detection. Acta Radiol 48(6):695–703
27. Barrett T, Turkbey B, Choyke PL (2015) PI-RADS version 2: what
you need to know. Clin Radiol 70(11):1165–1176
28. Wu LM, Xu JR, Ye YQ, Lu Q, Hu JN (2012) The clinical value of
diffusion-weighted imaging in combination with T2-weighted
imaging in diagnosing prostate carcinoma: a systematic review and
meta-analysis. Am J Roentgenol 199(1):103–110
29. Tan CH, Wei W, Johnson V, Kundra V (2012) Diffusion-weighted
MRI in the detection of prostate cancer: meta-analysis. Am J
Roentgenol 199(4):822–829
30. Godley KC, Syer TJ, Toms AP, et al. (2017) Accuracy of high
b-value diffusion-weighted MRI for prostate cancer detection: a
meta-analysis. Acta Radiol. http://doi.org/10.1177/028418511770
2181
T. J. Syer et al.: The diagnostic accuracy of high b-value diffusion- and T2-weighted imaging
31. Rosenkrantz AB, Chandarana H, Hindman N, et al. (2013) Com-
puted diffusion-weighted imaging of the prostate at 3 T: impact on
image quality and tumour detection. Eur Radiol 23(11):3170–3177
32. Vural M, Ertas G, Onay A, et al. (2014) Conspicuity of peripheral
zone prostate cancer on computed diffusion-weighted imaging:
comparison of cDWI1500, cDWI2000, and cDWI3000. Biomed
Res Int 2014:768291
33. Kuhl C, Bruhn R, Kra¨mer N, et al. (2017) Abbreviated bipara-
metric prostate MR imaging in men with elevated prostate-specific
antigen. Radiology 000:170129
34. Metens T, Miranda D, Absil J, Matos C (2012) What is the optimal
b value in diffusion-weighted MR imaging to depict prostate cancer
at 3T? Eur Radiol 22(3):703–709
35. Wang X, Qian Y, Liu B, et al. (2014) High-b-value diffusion-
weighted MRI for the detection of prostate cancer at 3 T. Clin
Radiol 69(11):1165–1170
36. Peng Y, Jiang Y, Antic T, et al. (2014) Apparent diffusion coeffi-
cient for prostate cancer imaging: Impact of b values. Am J
Roentgenol 202(3):W247–W253
37. Thormer G, Otto J, Horn LC, et al. (2015) Non-invasive estimation
of prostate cancer aggressiveness using diffusion-weighted MRI
and 3D proton MR spectroscopy at 3.0T. Acta Radiol
56(1):121–128
38. Kim CK, Park BK, Kim B (2010) Diffusion-weighted MRI at 3 T
for the evaluation of prostate cancer. Am J Roentgenol
194(6):1461–1469
39. Augustin H, Erbersdobler A, Hammerer PG, Graefen M, Huland
H (2004) Prostate cancers in the transition zone: part 2; clinical
aspects. BJU Int 94(9):1226–1229
40. Greene DR, Wheeler TM, Egawa S, Weaver RP, Scardino PT
(1991) Relationship between clinical stage and histological zone of
origin in early prostate cancer: morphometric analysis. Br J Urol
68(5):499–509
41. Rosenkrantz AB, Lim RP, Haghighi M, et al. (2013) Comparison
of interreader reproducibility of the prostate imaging reporting and
data system and Likert scales for evaluation of multiparametric
prostate MRI. Am J Roentgenol 201(4):W612–W618
42. Muller BG, Shih JH, Sankineni S, et al. (2015) Prostate cancer:
interobserver agreement and accuracy with the revised prostate
imaging reporting and data system at multiparametric mr imag-
ing1. Radiology 277(3):741–750
43. Agha M, Eid AF (2015) 3 Tesla MRI surface coil: is it sensitive for
prostatic imaging? Alex J Med 51(2):111–119
44. Bains LJ, Studer UE, Froehlich JM, et al. (2014) Diffusion-
weighted magnetic resonance imaging detects significant prostate
cancer with high probability. J Urol 192(3):737–742
45. Baur A, Daqqaq T, Wagner M, et al. (2016) T2- and diffusion-
weighted magnetic resonance imaging at 3T for the detection of
prostate cancer with and without endorectal coil: an intraindividual
comparison of image quality and diagnostic performance. Eur J
Radiol 6(85):1075–1084
46. Brendle C, Martirosian P, Schwenzer N, et al. (2016) Diffusion-
weighted imaging in the assessment of prostate cancer: comparison
of zoomed imaging and conventional technique. Eur J Radiol
5(85):893–900
47. Costa D, Yuan Q, Xi Y, et al. (2016) Comparison of prostate
cancer detection at 3-T MRI with and without an endorectal coil: a
prospective, Paired-patient study. Urol Oncol 6(34):255
48. Doo KW, Sung DJ, Park BJ, et al. (2012) Detectability of low and
intermediate or high risk prostate cancer with combined T2-
weighted and diffusion-weighted MRI. Eur Radiol 22(8):1812–1819
49. Haider MA, Van Der Kwast TH, Tanguay J, et al. (2007) Com-
bined T2-weighted and diffusion-weighted MRI for localization of
prostate cancer. Am J Roentgenol 189(2):323–328
50. Iwazawa J, Mitani T, Sassa S, Ohue S (2011) Prostate cancer
detection with MRI: is dynamic contrast-enhanced imaging neces-
sary in addition to diffusion-weighted imaging? Diagn Interv
Radiol 17(3):243–248
51. Katahira K, Takahara T, Kwee TC, et al. (2011) Ultra-high-b-
value diffusion-weighted MR imaging for the detection of prostate
cancer: evaluation in 201 cases with histopathological correlation.
Eur Radiol 21(1):188–196
52. Lim HK, Kim JK, Kim KA, Cho K-S (2009) Prostate cancer:
apparent diffusion coefficient map with T2-weighted images for
detection–a multireader study. Radiology 250(1):145–151
53. Loggitsi D, Gyftopoulos A, Economopoulos N, et al. (2017)
Multiparametric magnetic resonance imaging of the prostate for
tumour detection and local staging: imaging in 1.5T and
histopathologic correlation. Can Assoc Radiol J 68(4):379–386
54. Ohgiya Y, Suyama J, Seino N, et al. (2012) Diagnostic accuracy of
ultra-high-b-value 3.0-T diffusion-weighted MR imaging for
detection of prostate cancer. Clin Imaging 36(5):526–531
55. Rosenkrantz AB, Mannelli L, Kong X, et al. (2011) Prostate can-
cer: utility of fusion of T2-weighted and high b-value diffusion-
weighted images for peripheral zone tumor detection and local-
ization. J Magn Reson Imaging 34(1):95–100
56. Rosenkrantz AB, Kim S, Campbell N, et al. (2015) Transition zone
prostate cancer: revisiting the role of multiparametric MRI at 3 T.
AJR Am J Roentgenol 204(3):W266–W272
57. Shimofusa R, Fujimoto H, Akamata H, et al. (2005) Diffusion-
weighted imaging of prostate cancer. J Comput Assist Tomogr
29(2):149–153
58. Shinmoto H, Tamura C, Soga S, et al. (2015) Anterior prostate
cancer: diagnostic performance of T2-weighted MRI and an
apparent diffusion coefficient map. AJR Am J Roentgenol
205(2):W185–W192
59. Stanzione A, Imbriaco M, Cocozza S, et al. (2016) Biparametric 3T
magnetic resonance imaging for prostatic cancer detection in a
biopsy-naı¨ve patient population: a further improvement of PI-
RADS v2? Eur J Radiol 12(85):2269–2274
60. Tanimoto A, Nakashima J, Kohno H, Shinmoto H, Kuribayashi S
(2007) Prostate cancer screening: the clinical value of diffusion-
weighted imaging and dynamic MR imaging in combination with
T2-weighted imaging. J Magn Reson Imaging 25(1):146–152
61. Thestrup K, Logager V, Baslev I, et al. (2016) Biparametric versus
multiparametric MRI in the diagnosis of prostate cancer. Acta
Radiol Open 8(5):205846011666304
62. Ueno Y, Takahashi S, Ohno Y, et al. (1048) Computed diffusion-
weighted MRI for prostate cancer detection: the influence of the
combinations of b-values. Br J Radiol 2015(88):20140738
63. Vargas HA, Akin O, Franiel T, Mazaheri Y, et al. (2011) Diffusion-
weighted endorectal MR imaging at 3 T for prostate cancer: tumor
detection and assessment of aggressiveness. Radiology
259(3):775–784
64. Yoshimitsu K, Kiyoshima K, Irie H, et al. (2008) Usefulness of
apparent diffusion coefficient map in diagnosing prostate carci-
noma: correlation with stepwise histopathology. J Magn Reson
Imaging 27(1):132–139
65. Yoshizako T, Wada A, Hayashi T, et al. (2008) Usefulness of dif-
fusion-weighted imaging and dynamic contrast-enhanced magnetic
resonance imaging in the diagnosis of prostate transition-zone
cancer. Acta Radiol 49(10):1207–1213
T. J. Syer et al.: The diagnostic accuracy of high b-value diffusion- and T2-weighted imaging
